Fluidic Analytics is a Cambridge, UK–based developer of tools that characterize proteins in solution using a proprietary technology platform from the University of Cambridge. The platform is designed to give deep insights into how proteins fold, aggregate and interact, characterizing them precisely as they exist in the body. Led by CEO Andrew Lynn, the company’s products aim to help researchers understand mechanisms underlying conditions such as Alzheimer’s disease, enable pharmaceutical companies to develop effective drugs, and expand access to accurate diagnostics in clinical and near-patient settings. Fluidic plans to continue the commercial roll-out of its lab-tools pipeline and to develop further clinical applications of its technology. Financially, the company raised $31M to support these commercial and clinical development efforts. Fluidic Analytics develops protein characterization technologies and laboratory research tools that enable rapid, accurate and cost‑effective protein analysis. Its product line targets key market segments including protein quantitation, quantitative immunoassays and protein–protein interactions. The technology originated in the laboratory of Professor Tuomas Knowles at the University of Cambridge. The company will use the proceeds from the fundraise to advance its line of laboratory research tools. It is bringing products to market initially in the research tools market, then in clinical diagnostics and ultimately in consumer healthcare. The company is led by CEO Andrew Lynn. Fluidic Analytics is a 2013 spin-out from the Department of Chemistry at the University of Cambridge with operations in Cambridge, UK. The company designs, develops and manufactures tools for fast, convenient and accurate characterisation of proteins in laboratory research as well as medical and consumer applications. Its flagship product in development is the Flow Mk-1, a research tool that enables high-sensitivity measurement in seconds of protein size and concentration in their natural state using samples as small as one microlitre. The company received a £250k Development of Prototype Award from Innovate UK to support development of a working pre-production prototype of the Flow Mk-1. This award follows a £100k Smart Proof of Concept Award received one year earlier. Investors in the company include Cambridge Enterprise, DFJ Esprit, IQ Capital, Parkwalk, and Amadeus Capital Partners. Fluidic Analytics is positioning to bring the first of its products to the research market. Fluidic Analytics is developing a line of tools for the rapid, accurate and cost-effective analysis of proteins and other biomolecular species. The company combines a microfluidics platform developed at the University of Cambridge with efficient manufacturing and design principles. It aims to be a leading provider of products that enable breakthrough advances in fundamental protein science, drug development and diagnostics. Fluidic Analytics focuses on making protein characterisation faster, more precise, more convenient, more cost-effective and more accurate to help scientists and healthcare providers. Parkwalk have recently closed an investment in Fluidic Analytics for the University of Cambridge Enterprise Fund II and Parkwalk Funds. More detail can be seen on the company’s website.

Total raised

$38M

Funding rounds

4

Latest round

Equity

Latest activity

Nov 2018